$KNF

Knife River Corp (KNF): Results of Operations and Financial Condition

Knife River Corp (KNF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 a2026q2ex99.htm KKNIFE RIVER CORPORATION EX-99 Document KNIFE RIVER CORPORATION REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS • Double-digit volume and gross profit growth across material product lines • 20% growth in contracting services revenue • Sequentially increased

Original reporting
Published Aug 4, 2026, 12:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$KNF
Bullish
high confidence
Mentioned
$KNF
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$KNFBullishHigh
01

Why it matters

Traders can update models using the raised revenue and Adjusted EBITDA ranges, plus volume and pricing expectations by product line and the $1.2B contracting backlog trajectory.

02

Market read

Raised FY 2026 guidance with double-digit revenue growth and higher backlog is the core repricing catalyst, partially offset by margin headwinds and regional variability.

03

What to watch

Segment EBITDA margin declines in some regions and the note that guidance excludes future acquisitions may limit how much of the upside is organic.

Relevance 7/10Novelty 9/10Timing: guidance and Q2 results released pre-market today (Aug 4, 2026)

Background

This is Knife River’s SEC Form 8-K (Item 2.02) reporting Q2 2026 results and full-year 2026 guidance.

Company-level read

Ticker impact

$KNFBullishHigh confidence
Context

Knife River reported Q2 2026 results and raised full-year 2026 revenue and aggregate volume guidance, with backlog up to $1.2B.

Expected impact

Likely positive near-term bias as traders reprice FY 2026 expectations; margin commentary may temper upside.

Evidence & confidence

The filing is a primary disclosure (8-K) with specific Q2 datapoints and explicit full-year guidance ranges, including backlog and pricing/volume expectations.

Market effects

Signals strength in construction materials demand and contracting services pull-through, potentially supportive for aggregates and asphalt peers.

Regional segment commentary highlights weather and project phasing impacts in Oregon/Hawaii/Alaska versus strength in Mountain and Central regions.

Limited direct global linkage; primarily US construction cycle exposure.

Counterpoint

Margin pressure from energy costs and non-recurring asset-sale gains could mean guidance improvement is more volume-led than profit-led.

Key entities

  • Knife River Corporation

    Aggregates-based, vertically integrated construction materials and contracting services company reporting Q2 results and raised FY 2026 guidance.

  • Brian Gray

    President and CEO providing commentary on demand, pricing, backlog, and margin headwinds.

Related articles

$KNFMed

Knife River Q2 Earnings Call Highlights

Knife River (NYSE:KNF) said some Texas highway work will shift into 2027, and changes in paving versus larger roadway expansion jobs reduced Q2 adjusted EBITDA by about $8 million. CFO Nathan Ring reported aggregate volumes up 14% and raised 2026 revenue to $3.4B-$3.6B while reaffirming adjusted EBITDA guidance of $520M-$560M. Backlog rose to $1.2B.

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.

$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

$KDPMed

Keurig Dr Pepper Inc. Q2 2026 Earnings Call Summary

Keurig Dr Pepper reported Q2 2026 results that exceeded expectations, citing double-digit U.S. Refreshment Beverages growth and day-one integration of JDE Peet's. Dr Pepper Zero Sugar grew 30% in retail sales and energy reached 9% market share. U.S. Coffee faced margin pressure from hedging and tariffs. KDP reaffirmed low double-digit EPS growth for 2026 and low-double-digit legacy growth at the high end of 4% to 6%.

$TAPMed

Molson Coors Beverage Company Q2 2026 Earnings Call Summary

Molson Coors reported Q2 2026 volume pressure tied to an energy and inflation shock after conflict in Iran, plus stronger promotions and geopolitical uncertainty in EMEA and APAC. The company reaffirmed FY2026 guidance, citing improving U.S. industry volumes, 1% to 2% annual U.S. price increases, and Midwest Premium aluminum COGS above $130 million, partly hedged. It also outlined a $450 million cost-savings plan and Atomic Brands integration.